Biblio

Found 5 results
Filters: Keyword is Receptor, ErbB-2  [Clear All Filters]
2022
Osdoit M, Yau C, W Symmans F, Boughey JC, Ewing CA, Balassanian R, Chen Y-Y, Krings G, Wallace AM, Zare S, et al. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 ;157(11):1034-1041.
Johansson A, Yu NY, Iftimi A, Tobin NP, Veer Lvan 't, Nordenskjöld B, Benz CC, Fornander T, Perez-Tenorio G, Stål O, et al. Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature. Int J Cancer. 2022 ;150(12):2072-2082.
A Chien J, Kyalwazi B, Esserman LJ. Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting. Cell Rep Med. 2022 ;3(6):100664.
Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRong Evely, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 ;40(6):609-623.e6.
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy A-S, Laé M, Reyal F, Sonke GS, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022 ;23(1):149-160.